Insulet (Nasdaq:PODD) announced today that it is rolling out new algorithm enhancements for its Omnipod 5 automated insulin delivery system. The company also expanded its compatibility with Abbott sensors, adding the option of pairing Omnipod 5 with FreeStyle Libre 3 Plus. Acton, Massachusetts-based Insulet won FDA clearance for its algorithm enhancements in December 2025. The […]
abbott
MiniMed adds Abbott dual glucose-ketone sensor to portfolio, posts Q4 sales beat
MiniMed (Nasdaq:MMED) announced today that it expanded its agreement with Abbott (NYSE:ABT) to add more sensors to its portfolio. The company also announced fourth-quarter earnings results in tandem with the new Abbott integration. MiniMed has an existing partnership with Abbott through a collaboration between the companies agreed in 2024. They integrated Instinct, a sensor made by […]
Abbott wins CE mark for dual glucose-ketone sensor
Abbott (NYSE:ABT) announced today that it received CE mark approval for its dual glucose-ketone sensing technology for people with diabetes. The company said its dual sensor marks a world first, continuously measuring glucose and ketone levels every minute. Branded as Libre Duo and Libre Duo 10 Day, the sensors provide real-time visibility into glucose levels […]
Abbott has positive drug-eluting scaffold data
Abbott (NYSE:ABT) today shared promising 30-day results for its Esprit BTK everolimus-eluting resorbable scaffold system. Esprit features materials similar to dissolving sutures. Unlike metal stents, it’s not a permanent implant, providing support for blocked vessels only for a few months after the blockage is cleared. At that point, the vessel can remain open on its […]
Abbott wins appeal for preliminary injunction against Sinocare in CGM patent spat
The Unified Patent Court (UPC) Court of Appeal granted Abbott (NYSE:ABT) a preliminary injunction in its patent battle against Sinocare. Abbott’s preliminary injunction victory means Sinocare is banned from selling its iCan i3 continuous glucose monitor (CGM) offering in UPC territory. The UPC decision overturned a prior ruling from a local division (LD) of The […]
Abbott CEO is bullish on CGM market despite analyst concerns
Abbott (NYSE:ABT) CEO Robert B. Ford remains optimistic about the company’s opportunity in the continuous glucose monitor (CGM) market. The company reported its first-quarter earnings today, which included $2 billion in FreeStyle Libre CGM sales, growing 7.5%. Abbott noted a delay in the renewal process related to an international tender, as well as an expected […]
Abbott launches Lingo OTC CGM at Best Buy through Withings bundle
Abbott (NYSE:ABT) today said it launched a new bundle with Withings for its Lingo over-the-counter glucose biosensor at Best Buy. Lingo features a biosensor and mobile app designed for customers who want to improve their overall health and wellness. The company built Lingo on its FreeStyle Libre continuous glucose monitor (CGM) technology platform. The consumer […]
Abbott earns CMS reimbursement win for Esprit drug-eluting scaffold
An Abbott (NYSE:ABT) official has shared a significant reimbursement win for its Esprit BTK drug-eluting scaffold system. On LinkedIn, SVP and President of Abbott Vascular, Julie Tyler, posted that the Centers for Medicare & Medicaid Services (CMS) approved transitional pass-through (TPT) payment status for Esprit BTK. TPT, a three-year program, ensures that Medicare beneficiaries can […]
The biggest diabetes tech news out of ATTD 2026
Diabetes technology innovators gathered in Barcelona last week for the 19th annual Advanced Technologies and Treatments for Diabetes Conference (ATTD 2026). At ATTD 2026, a range of companies shared the latest updates, including product launches, new clinical data, enhancements to existing offerings and more. Topics included automated insulin delivery, continuous glucose monitors (CGMs), and breakthroughs […]
Abbott study highlights better glucose outcomes with Libre CGM in type 2 diabetes on basal insulin
Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs). The FreeDM2 randomized controlled trial evaluated whether real-time CGM can help people with type 2 diabetes using basal insulin improve their glucose management. It took place across 24 clinical sites in the UK, evaluating 303 participants. […]
